Brick & Kyle Associates’s iShares Biotechnology ETF IBB Stock Holding History

Brick & Kyle Associates’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$343K	Hold	2,029	–	–	0.11%	76
2026 Q1	$343K	Sell	2,029 -74	-4%	-$12.7K	0.11%	76
2025 Q4	$355K	Hold	2,103	–	–	0.13%	58
2025 Q3	$304K	Sell	2,103 -40	-2%	-$5.46K	0.11%	59
2025 Q2	$296K	Buy	+2,143	New	+$263K	0.13%	59
2025 Q1	–	Sell	-2,143	Closed	-$283K	–	57
2024 Q4	$283K	Sell	2,143 -25	-1%	-$3.52K	0.12%	59
2024 Q3	$316K	Buy	2,168 +1	+0%	+$145	0.14%	54
2024 Q2	$297K	Sell	2,167 -210	-9%	-$28K	0.12%	60
2024 Q1	$317K	Hold	2,377	–	–	0.14%	57
2023 Q4	$323K	Sell	2,377 -29	-1%	-$3.54K	0.16%	55
2023 Q3	$294K	Hold	2,406	–	–	0.16%	57
2023 Q2	$306K	Sell	2,406 -120	-5%	-$15.6K	0.16%	54
2023 Q1	$326K	Sell	2,526 -60	-2%	-$7.85K	0.19%	54
2022 Q4	$340K	Buy	2,586 +1	+0%	+$129	0.2%	55
2022 Q3	$304K	Sell	2,585 -55	-2%	-$6.83K	0.18%	55
2022 Q2	$310K	Hold	2,640	–	–	0.17%	57
2022 Q1	$344K	Hold	2,640	–	–	0.17%	56
2021 Q4	$403K	Hold	2,640	–	–	0.19%	55
2021 Q3	$431K	Hold	2,640	–	–	0.22%	54
2021 Q2	$434K	Hold	2,640	–	–	0.23%	53
2021 Q1	$402K	Buy	2,640 +30	+1%	+$4.76K	0.22%	55
2020 Q4	$394K	Sell	2,610 -140	-5%	-$20K	0.25%	53
2020 Q3	$372K	Hold	2,750	–	–	0.26%	50
2020 Q2	$373K	Hold	2,750	–	–	0.28%	50
2020 Q1	$296K	Sell	2,750 -75	-3%	-$8.63K	0.28%	55
2019 Q4	$343K	Hold	2,825	–	–	0.26%	54
2019 Q3	$302K	Sell	2,825 -225	-7%	-$23.6K	0.25%	53
2019 Q2	$329K	Hold	3,050	–	–	0.31%	51
2019 Q1	$341K	Hold	3,050	–	–	0.35%	46
2018 Q4	$294K	Buy	+3,050	New	+$324K	0.28%	67
2018 Q2	$346K	Hold	3,150	–	–	0.27%	71
2018 Q1	$336K	Hold	3,150	–	–	0.27%	71
2017 Q4	$336K	Hold	3,150	–	–	0.27%	73
2017 Q3	$350K	Hold	3,150	–	–	0.28%	73
2017 Q2	$326K	Hold	3,150	–	–	0.28%	75
2017 Q1	$308K	Sell	3,150 -150	-5%	-$14.4K	0.24%	77
2016 Q4	$292K	Hold	3,300	–	–	0.23%	76
2016 Q3	$318K	Hold	3,300	–	–	0.26%	75
2016 Q2	$283K	Hold	3,300	–	–	0.23%	75
2016 Q1	$287K	Sell	3,300 -1,425	-30%	-$127K	0.25%	75
2015 Q4	$533K	Hold	4,725	–	–	0.47%	53
2015 Q3	$478K	Sell	4,725 -150	-3%	-$18K	0.45%	53
2015 Q2	$600K	Hold	4,875	–	–	0.5%	51
2015 Q1	$558K	Hold	4,875	–	–	0.48%	52
2014 Q4	$493K	Buy	+4,875	New	+$474K	0.43%	56

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Brick & Kyle Associates's IBB Position: Q2 2026 in Review

Brick & Kyle Associates held its iShares Biotechnology ETF (IBB) position steady in Q2 2026 at 2,029 shares worth $343K. The position accounts for 0.11% of the portfolio, ranked #76.

Brick & Kyle Associates first reported a position in IBB in Q4 2014 and has held it in 45 quarters since. The position peaked at $600K in Q2 2015. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Brick & Kyle Associates held 2,029 shares of iShares Biotechnology ETF worth $343K as of Q2 2026.
Brick & Kyle Associates left its iShares Biotechnology ETF share count unchanged in Q2 2026.
iShares Biotechnology ETF made up 0.11% of Brick & Kyle Associates's portfolio in Q2 2026, its #76 holding.
Brick & Kyle Associates first reported a position in iShares Biotechnology ETF in Q4 2014 and has held it in 45 quarters since.
Brick & Kyle Associates's iShares Biotechnology ETF position peaked at $600K in Q2 2015.
954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Brick & Kyle Associates's 13F filing for Q2 2026, filed 6 Aug 2026.